Sanofi’s Sarclisa Gets EMA Backing In Myeloma, Mirroring FDA OK
But Experts Doubt It Can Overtake J&J’s Entrenched Darzalex
Executive Summary
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.
You may also be interested in...
FDA Sarclisa Approval Marks Sanofi's Reentry Into Oncology
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
Patient-Centric: Evotec’s CSO Explains R&D Strategy
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk, Evotec Link Around Chronic Kidney Disease
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports